Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pulmonary Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pulmonary Other
    Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis - (BMJ)
    Size of Balloon Not a Significant Factor in Durable Airway Dilation for Lung Transplantation Patients: Presented at SIR - (DGDispatch)
    Misuse of Hydrocodone-Containing Cough Suppressant Linked to Life-Threatening Adverse Events - (DGNews)
    Nasal CPAP or intubation at birth for very preterm infants - (N Engl J Med)
    Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial - (JAMA)

    News archive

     Recent webcasts/CME - Pulmonary Other
      Pulmonary Arterial Hypertension: Optimizing Patient Managment in Clinical Practice
      New Concepts in Obstructive Airway Disease
      Primary Pulmonary Hypertension
      Obesity Hypoventilation Syndrome
      High-Altitude Pulmonary Edema: Prevention and Treatment

      Webcasts/CME archive

       Recent cases - Pulmonary Other
        Hairy Cell Leukaemia Presenting with Ascites, Pleural Effusion and Increased CA 125 Serum Level
        Severe Pulmonary Hypertension and Takayasu Arteritis
        Broncholithiasis: Case Report and Discussion with Focus on Radiographic Findings
        Bilateral Pleural Effusions Following Central Venous Cannulation
        VATS Intraoperative Tattooing to Facilitate Solitary Pulmonary Nodule Resection

        Cases archive
          




        my personal edition > pulmonary other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Bosentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Postpulmonary Endarterectomy Pulmonary Hypertension: Presented at ESC

        By Chris Berrie

        VIENNA, AUSTRIA -- September 14, 2007 -- The dual endothelin receptor antagonist bosentan provides significantly improved haemodynamics and decreased pulmonary vascular resistance (PVR) in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and with postpulmonary endarterectomy (PEA) pulmonary hypertension (PH), according to a study presented here at the European Society of Cardiology (ESC) Congress.

        The findings from a predefined subgroup analysis of the multicentre, prospective, randomised, double-blind, placebo-controlled Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension (BENEFIT) trial were presented on September 5th.

        Iris Lang, MD, Steering Committee Member and Professor in Vascular Biology, Division of Cardiology, Department of Internal Medicine 2, Medical University, Vienna, Austria, explained that CTEPH is an extraordinary subset within PH, and appears as an obstruction due to build-up of material in the pulmonary arteries, according to the 'Venice' clinical classification of pulmonary hypertension (PH).

        If CTEPH is treated surgically, "it makes the patient healthy and happy again, and this actually means, to cure the disease," Dr. Lang said.

        However, PEA depends on CTEPH being operable with an acceptable operative risk, which is not always the case, she added. Problems can also arise from small vessel disease, mismatch between haemodynamics and extent of occlusions, or recurrent PH. It is estimated that CTEPH is inoperable in as many as 50% of cases.

        As an endothelin receptor antagonist, bosentan has emerged as a potential pharmacological treatment in such inoperable cases. Its effect has been linked to the upregulation of endothelin receptors distal to the ligation in pulmonary arteries in animal models of CTEPH.

        The aim of the main BENEFIT trial was to examine the efficacy of bosentan, as well as its safety and tolerability, in patients with inoperable CTEPH and persistent/recurrent PH post-PEA. The present predefined subgroup analysis compared the treatment effects between patients with inoperable CTEPH (n = 113) and those with persistent/recurrent PH (n = 44).

        The main study design had an initial 3-week screening period, followed by patient randomisation (week 0) to either placebo or bosentan 62.5 mg BID. After 4 weeks, bosentan was uptitrated to 125 mg BID, and the trial was terminated at week 16.

        The key result of the main BENEFIT trial was that bosentan provided clinically relevant improvements in cardiac haemodynamics -- decreased PVR, increased cardiac output, and decreased N-terminal proB-type natriuretic peptide (NT-proBNP). This was accompanied by no effects on exercise capacity and an improvement in the Borg dyspnoea index. In addition, bosentan was shown to be safe and well tolerated by patients, consistent with previous controlled trials.

        In Dr. Lang's subgroup analysis, treatment effect (TE) was expressed as a percentage of baseline PVR at week 16.

        Bosentan was seen to significantly reduce PVR both for inoperable CTEPH (TE, -17.5%; 95% confidence interval [CI], -27.0, -6.7) and for persistent/recurrent PH (TE, -32.5%; 95% CI, -44.4, -18.1).

        Borg dyspnoea index also showed a significant improvement in CTEPH (TE, -0.8; 95% CI, -1.6, -0.1). This effect was not seen with persistent/recurrent PH (TE, +0.1; 95% CI, -0.9, +1.2).

        In contrast, the change in the 6-minute walk was not significant in either the inoperable CTEPH group (TE, +8.8 m; 95% CI, -22.5, +40.0) or the persistent/recurrent PH group (TE, -11.5 m; 95% CI, -39.6, +16.6).

        Similar significant effects were observed within each patient group for cardiac index, mean pulmonary arterial pressure, and NT-proBNP.

        Dr. Lang concluded that bosentan provided improved haemodynamics, decreased PVR and had positive effects on cardiac index, mean pulmonary arterial pressure and NT-proBNP. Therefore, she said, "I would like to propose that this drug will be a therapeutic option for patients without further hope in the inoperable form."

        Funding for this study was provided by Actelion Ltd.


        [Presentation title: Bosentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Post-Pulmonary Endarterectomy Pulmonary Hypertension. Abstract 4505]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send